Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16

European Journal of Preventive Cardiology

Volumn 21, Issue 2, 2014, Pages 192-202

  Mehta, Suneela ^a   Wells, Sue ^a   Grey, Corina ^a   Riddell, Tania ^a   Kerr, Andrew ^b   Marshall, Roger ^a   Ameratunga, Shanthi ^a   Harrison, Jeff ^a   Kenealy, Tim ^a   Bramley, Dale ^c   Chan, Wing Cheuk ^b   Thornley, Simon ^a   Sundborn, Gerhard ^a   Jackson, Rod ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Division of Medicine Emergency and Integrated Care   (New Zealand)

^c WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Cardiovascular diseases; medication dispensing; medication maintenance; primary prevention; secondary prevention

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW ZEALAND; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; YOUNG ADULT;

CARDIOVASCULAR DISEASES; MEDICATION DISPENSING; MEDICATION MAINTENANCE; PRIMARY PREVENTION; SECONDARY PREVENTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DECISION SUPPORT SYSTEMS, CLINICAL; DECISION SUPPORT TECHNIQUES; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84893464416     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312462150     Document Type: Article

References (29)

1. The assessment and management of cardiovascular risk. Wellington: New Zealand Guidelines Group ; 2003 :
2. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996 ; 164: 208-211
3. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005 ; 165: 1147-1152
4. Jackevicius CA, Mamdani M, Tu J. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002 ; 288: 462-467
5. Newby LK, LaPointe N, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006 ; 113: 203-212
6. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in statin therapy in the elderly. JAMA. 2002 ; 288: 455-461
7. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998 ; 279: 1458-1462
8. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidaemic drugs - do rates reported in clinical trials reflect rates in primary care settings?. N Engl J Med. 1995 ; 332: 1125-1131
9. Ho PM, Bryson CL, Rumsfield JS. Medication adherence. Its importance in cardiovascular outcomes. Circulation. 2009 ; 119: 3028-3035
10. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008 ; 336: 1114-1117
11. Protection Study Collaborative Group Heart. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360: 7-22
12. Bannink L, Wells S, Broad J, et al. Web-based assessment of cardiovascular disease risk in routine primary care practice in New Zealand: the first 18,000 patients (PREDICT CVD-1). N Z Med J. 2006 ; 119 (1245). U2313 - U2313
13. Statistics New Zealand. Subnational population estimates tables. Available at www.stats.govt.nz/browse-for-stats/population/estimates-and- projections/subnational-pop-estimates-tables.aspx (2010, consulted June 2011).
14. Ministry of Health. National health index. Available at: www.nzhis.govt.nz/moh.nsf/pagesns/265?Open (2011, consulted September 2011).
15. New Zealand Health Information Service. Pharmaceutical information database (PHARMS). Available at: www.nzhis.govt.nz/moh.nsf/pagesns/485?Open (2006, consulted May 2010).
16. Salmond C, Crampton P NZDep2001 Index of deprivation. User's manual. Wellington: Wellington School of Medicine and Health Sciences ; 2002 :
17. Grey C, Wells L, Riddell T, et al. A comparative analysis of the cardiovascular disease risk factor profiles of Pacific peoples and Europeans living in New Zealand assessed in routine primary care: PREDICT CVD-11. N Z Med J. 2010 ; 123: 62-75
18. Mehta S, Wells L, Riddell T, et al. Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15). J Prim Health Care. 2011 ; 3: 93-101
19. Wells L, Furness S, Rafter N, et al. Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice. Eur J Prev Cardiol. 2008 ; 15: 173-178
20. Grover SA, Lowensteyn I, Joseph L, et al. Discussing coronary risk with patients to improve blood pressure treatment: secondary results from the CHECK-UP study. J Gen Intern Med. 2009 ; 24: 33-39
21. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001 ; 22: 554-572
22. Kotseva K, Wood D, Backer GD, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Prev Cardiol. 2010 ; 17: 530-540
23. Kotseva K, Wood D, Backer GD, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Prev Cardiovasc Rehabil. 2009 ; 16: 121-137
24. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997 ; 18: 1569-1582
25. Kotseva K. Lessons from EUROASPIRE I,II and III surveys. Heart Metab. 2011 ; 50: 32-35
26. Heart Foundation. Know your numbers. Available at: www.knowyournumbers. co.nz (2010, consulted September 2011).
27. Jansen P, Smith K. Maori experiences of primary health care: breaking down the barriers. The New Zealand Family Physician. 2006 ; 33: 298-300
28. Osterberg L and Blaschke T. Adherence to medication. N Engl J Med 2005; 353.
29. Chang Wai K, Elley CR, Nosa V, et al. Perspectives on adherence to blood pressure-lowering medications among Samoan patients: qualitative interviews. J Prim Health Care. 2010 ; 2: 217-224